Evidence map›Paper›PMID 34209673›Full record

ArticleInternational journal of molecular sciences2021

Isabella Zanella, Eliana Zacchi, Simone Piva, Massimiliano Filosto, Giada Beligni, Diana Alaverdian, Sara Amitrano, Francesca Fava, Margherita Baldassarri, Elisa Frullanti and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Gender and genetic factors impacting COVID-19 severity.Journal of family medicine and primary care · 2021
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Isabella ZanellaDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-3902-3376
Eliana ZacchiDepartment of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.
Simone PivaUniversity Division of Anesthesiology and Critical Care Medicine, ASST Spedali Civili, 25123 Brescia, Italy.
Massimiliano FilostoDepartment of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-2852-7512
Giada BeligniMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Diana AlaverdianMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Sara AmitranoGenetica Medica, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.
Francesca FavaMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-4363-2353
Margherita BaldassarriMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0391-1980
Elisa FrullantiMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Ilaria MeloniMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
Alessandra RenieriMedical Genetics, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0846-9220
GEN-COVID Multicenter Study
GEVACOBA Study Group
Francesco CastelliDepartment of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-9161-7804
Eugenia Quiros-RoldanDepartment of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-1452-9100
University of Siena · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITAzienda Ospedaliera Universitaria Senese · ITUniversity of Brescia · IT

Funding

Azienda Ospedaliero-Universitaria Senese "Bando Ricerca COVID-19 Toscana"charity fund 2020 from Intesa San Paolo N. B/2020/0119 "Identificazione delle basi genetiche determinanti la variabilità clinica della risposta a COVID-19 nella popolazione italianaMinistero dell'Istruzione, dell'Università e della Ricerca project "Dipartimenti di Eccellenza 2018-2020" to the Department of Medical Biotechnologies University of Siena, Italy (Italian D.L. n.18 March 17, 2020)private donors for COVID-19 researchUniversità degli Studi di Brescia ex 60% (I.Z.)ViiV Healthcare unconditional grant (E.Q-R)
6 · The paper itself

Abstract

A cytokine storm, autoimmune features and dysfunctions of myeloid cells significantly contribute to severe coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Genetic background of the host seems to be partly responsible for severe phenotype and genes related to innate immune response seem critical host determinants. The

Indexed as

Microsatellite RepeatsAdultAgedAge FactorsAmyotrophic Lateral SclerosisC9orf72 ProteinCOVID-19FemaleGenetic Predisposition to DiseaseGenotypeHumansLogistic ModelsMaleMiddle AgedOdds RatioRisk FactorsC9orf72 ProteinC9orf72 protein, humanautophagyC9orf72COVID-19genetic riskinnate immunityintermediate allelesSARS-CoV-2

Identifiers

PMID34209673
PMCPMC8268051
OpenAlexW3175225809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.